CTOs on the Move

Merz Pharmaceuticals

www.merzusa.com

 
Merz Pharmaceuticals is a Greensboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.merzusa.com
  • 4215 Tudor Ln
    Greensboro, NC USA 27410
  • Phone: 336.856.2003

Executives

Name Title Contact Details

Similar Companies

UroGen

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.

Medaus Pharmacy

Medaus Pharmacy is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.

Registrat

Registrat, Inc. is a Lexington, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Cell Technology

Advanced Cell Technology, Inc. is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.